Treatment trends in metastatic pancreatic cancer patients: Is it time to change?

Digestive and Liver Disease

Volumn 43, Issue 3, 2011, Pages 225-230

  Reni, Michele ^a   Pasetto, Lara Maria ^b   Passardi, Alessandro ^c   Milella, Michele ^d   Mambrini, Andrea ^e   Cereda, Stefano ^a   Aprile, Giuseppe ^f   Tronconi, Maria Chiara ^g   Berardi, Rossana ^h   Cordio, Stefano ⁱ   Sartori, Nora ^j   Rognone, Alessia ^a   Pederzoli, Paolo ^j   Falconi, Massimo ^j  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e Civ Osp   (Italy)

^f UNIVERSITY HOSPITAL OF UDINE   (Italy)

^g Department of Oncology Humanitas ^*  (Italy)

^h UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

ⁱ Garibaldi Nesima Hospital   (Italy)

^j Chirurgia Generale B   (Italy)

more..

Author keywords

Chemotherapy; Gemcitabine; Pancreatic cancer; Survey

Indexed keywords

CISPLATIN; FLUOROPYRIMIDINE; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79551489954     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.09.010     Document Type: Article

References (25)

1. Greene F.L., Page D., Fleming I.D., et al. Exocrine pancreas. AJCC cancer staging manual 2002, Springer, New York, p. 157-64. 6th ed.
2. Berlin J.D., Catalano P., Thomas J.P., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002, 20:3270-3275.
3. Moore M.J., Hamm J., Dancey J., et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3296-3302.
4. Rocha Lima C.M., Green M.R., Rotche R., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004, 22:3776-3783.
5. Heinemann V., Quietzsch D., Gieseler F., et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. J Clin Oncol 2006, 24:3946-3952.
6. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with Oxaliplatin compared with Gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23:3509-3516.
7. Oettle H., Richards D., Ramanathan R.K., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005, 16:1639-1645.
8. Herrmann R., Bodoky G., Ruhstaller T., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007, 25:2212-2217.
9. Cunningham D., Chau I., Stocken C., et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 2005, 3:12. [suppl. abstr. PS 11].
10. Sultana A., Tudur Smith C., Cunningham D., et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2008, 25:2607-2615.
11. Colucci G., Labianca R., Di Costanzo F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010, 28:1645-1651.
12. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966.
13. Cantore M., Fiorentini G., Luppi G., et al. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective randomized phase III trial of the Italian society for integrated locoregional therapy in oncology. J Chemother 2004, 16:34-39.
14. Reni M., Cordio S., Milandri C., et al. Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol 2005, 6:369-376.
15. Reni M., Cereda S., Galli L. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen. Cancer Lett 2007, 256:25-28.
16. Conroy T., Desseigne F., Ychou M., et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. Proc Am Soc Clin Oncol 2010, 28. [abstr. 4010].
17. Brambs H.J., Claussen C.D. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy 1993, 25:58-68.
18. Burris H.A., Moore M.J., Andersen J., et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
19. Reni M., Cereda S., Bonetto E., et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2007, 59:361-367.
20. Cereda S., Rognone A., Ghidini M., et al. A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel. Proc Am Soc Clin Oncol 2009, 27. [abstr 4614].
21. Tajiri H., Yoshimori M., Okazaki N., et al. Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer. Oncology 1991, 48:18-21.
22. Ducreux M., Rougier P., Pignon J.P., et al. A randomized trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002, 13:1185-1191.
23. Colucci G., Giuliani F., Gebbia V., et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomised phase III study of the Gruppo Oncologico dell'Italia Meridionale. Cancer 2002, 94:902-910.
24. Poplin E., Feng Y., Berlin J., et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27:3778-3785.
25. Reni M., Bonetto E., Cordio S., et al. Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology 2006, 6:454-463.